menu
    • menu
    [{"orgOrder":0,"company":"3PBiovian","sponsor":"Eleva","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Factor H","moa":"CFH","graph1":"Nephrology","graph2":"Preclinical","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3PBiovian \/ 3PBIOVIAN","highestDevelopmentStatusID":"4","companyTruncated":"3PBiovian \/ 3PBIOVIAN"},{"orgOrder":0,"company":"3PBiovian","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Isunakinra","moa":"interleukin-1 (IL-1) receptor antagonists","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3PBiovian \/ Buzzard Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"3PBiovian \/ Buzzard Pharmaceuticals"},{"orgOrder":0,"company":"3PBiovian","sponsor":"ANL Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"ANL-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ Biovian","highestDevelopmentStatusID":"4","companyTruncated":"3PBiovian \/ Biovian"},{"orgOrder":0,"company":"3PBiovian","sponsor":"Toleranzia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3PBiovian \/ Toleranzia"},{"orgOrder":0,"company":"3PBiovian","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3PBiovian \/ SpyBiotech"}]

    Find Clinical Drug Pipeline Developments & Deals by 3PBiovian

    Menu

    3PBiovian

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Factor H

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Recipient : Eleva

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eleva, 3PBIOVIAN Partner to Boost Capacity for Eleva’s Platform & Pipeline

                            Details : The collaboration aims to advance Factor H (CPV-104), a recombinant version of human complement Factor H, with a primary focus on delivering clinical data in C3 Glomerulopathy as the lead indication.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 04, 2025

                            Lead Product(s) : Factor H

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Recipient : Eleva

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANL-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : ANL Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer’s Disease

                            Details : The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufactu...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 18, 2022

                            Lead Product(s) : ANL-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : ANL Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isunakinra

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Buzzard Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            3P Biopharmaceuticals and Buzzard Pharmaceuticals Start a Collaboration to Develop a New Treatment to Combat S...

                            Details : 3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 07, 2021

                            Lead Product(s) : Isunakinra

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Buzzard Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : SpyBiotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement

                            Details : SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 27, 2020

                            Lead Product(s) : VLP Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : SpyBiotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOL2

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Toleranzia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            3P Bio and Toleranzia Enter Orphan Drug Partnership

                            Details : Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : TOL2

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Toleranzia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth